Iyer Arjun, Kumarasinghe Gayathri, Hicks Mark, Watson Alasdair, Gao Ling, Doyle Aoife, Keogh Anne, Kotlyar Eugene, Hayward Christopher, Dhital Kumud, Granger Emily, Jansz Paul, Pye Roger, Spratt Phillip, Macdonald Peter Simon
Heart & Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.
J Transplant. 2011;2011:175768. doi: 10.1155/2011/175768. Epub 2011 Aug 1.
Primary graft failure (PGF) is a devastating complication that occurs in the immediate postoperative period following heart transplantation. It manifests as severe ventricular dysfunction of the donor graft and carries significant mortality and morbidity. In the last decade, advances in pharmacological treatment and mechanical circulatory support have improved the outlook for heart transplant recipients who develop this complication. Despite these advances in treatment, PGF is still the leading cause of death in the first 30 days after transplantation. In today's climate of significant organ shortages and growing waiting lists, transplant units worldwide have increasingly utilised "marginal donors" to try and bridge the gap between "supply and demand." One of the costs of this strategy has been an increased incidence of PGF. As the threat of PGF increases, the challenges of predicting and preventing its occurrence, as well as the identification of more effective treatment modalities, are vital areas of active research and development.
原发性移植心脏功能衰竭(PGF)是心脏移植术后即刻发生的一种灾难性并发症。它表现为供体心脏严重的心室功能障碍,并伴有显著的死亡率和发病率。在过去十年中,药物治疗和机械循环支持方面的进展改善了发生这种并发症的心脏移植受者的预后。尽管在治疗方面取得了这些进展,但PGF仍然是移植后30天内的主要死亡原因。在当今器官严重短缺且等待名单不断增加的情况下,全球各移植单位越来越多地使用“边缘供体”来试图弥合“供需”差距。这一策略的代价之一是PGF的发生率增加。随着PGF威胁的增加,预测和预防其发生的挑战以及确定更有效的治疗方式,是积极开展研究和开发的重要领域。